This is an HTML version of an attachment to the Freedom of Information request 'Comunicaciones CCAES - ECDC'.

From:
@mscbs.es
To:
Duty EI 24/7
Subject:
RE: Request for information - cases of COVID-19 in vaccinated nursing home guests
Date:
15 April 2021 20:46:46
Attachments:
image001.gif
image002.png
image003.png
image004.png
image005.png
Informe GIV comunicacion 20210415.pdf
EXTERNAL EMAIL - Do not click on any links, open attachments or reply, unless you recognise the
sender's email address (
@mscbs.es) and believe the content is safe.
Please, find my answers in your own text in red.
I only could read your mail few minutes ago and it is late. I will send you better information tomorrow.
 
Fernando
 
De: Duty EI 24/7 [mailto:xxxxxxx@xxxx.xxxxxx.xx] 
Enviado el: jueves, 15 de abril de 2021 8:14
Para: Simón Soria. Fernando
CC: Duty EI 24/7
Asunto: Request for information - cases of COVID-19 in vaccinated nursing home guests
 
Dear Fernando,
ECDC is in the last stages of preparing guidance on vaccinated individuals, and we wanted to rapidly contact
you to see if we could gain a better understanding of the situation in Spain with regards to nursing homes and
potential cases of COVID-19 in vaccinated individuals.
For ease of reading and replying, allow us to list a number of questions here below in point form. Answers to
the following questions would be valuable:
1.  Have you identified outbreaks in LTCFs where residents and staff have been fully vaccinated? YES
2.  In the event that outbreaks have occurred in LTCFs where full vaccination coverage has been achieved,
for each LTCF, do you have information on:
a.  How many cases have been detected? Last week there were 4 OBs including 25 cases (one in a
facility for disabled people and 3 in nursing homes for elderly). Tomorrow we will give you more
detailed and accurate information, but as a rough estimation we are having between 2 and 6 OBs
per week and between 11 and 30 cases per week since coverage was above 80% with one dose.
b.  Was this among residents and/or staff? Both
c.  What was the vaccination status of the cases? Most of them were vaccinated, as expected in
highly vaccinated populations with vaccines that are not 100% effective. Incidences have being
around expected according to expected efficacy for first and second doses.
d.  Which vaccine product(s) have been used for vaccination in the LTCF? Pfizer and Moderna
e.  How long the last dose of vaccine was administrated in cases? The monitoring of OB in  LTCFs is
ongoing since May 2020 and therefore we have detected cases all along the vaccination process
including cases right after vaccination, up to three weeks after first dose, and different time
periods after second dose.
f.  Is there any information on disease severity? How many hospitalised? How many deaths? Cases
are, so far, either asymptomatic or mild. Very few had to be hospitalized and as far as I am aware
right now 3 died, but their symptoms were not very compatible with COVID-19 despite the virus
was identified by PCR. We are talking about very old and fragile people with high mortality rates.
g.  Do you have an overview of the vaccination status of all the LTCF residents and staff (i.e. are each
of the LTCFs considered “fully vaccinated”) where outbreaks have occurred? I attach the last
vaccination report where you can see the coverage (98.6% one dose and 91.3% two doses).
Almost same coverage among residents and among workers. Most LTCFs where OB occurred


were almost fully vaccinated.
h.  Do you have an overview, understanding of which SARS-CoV-2 variants have been involved? How
many samples of these patients have been sequenced? The information is available but I cannot
have it with such a short notice. I may get it tomorrow.
3.  What control measures are currently in place, and have any additional control measures been
implemented in response to these outbreaks? Transmission control measures in LTCFs have been only
slightly reduced because of vaccination so far. OBs in LTCFs are dealt with as in  any other setting,
independently of vaccination status. Probably this will be modified when higher coverage is reach in
general population.
We would highly appreciate your reply by today, Thursday the 15th April, COB.
We thank you very much in advance and look forward to hearing from you.
Kind regards,
24/7 Duty Officer
 
 
 
  
ECDC Logo
European Centre for Disease Prevention and Control (ECDC)
Gustav III:s boulevard 40, 169 73 Solna, Sweden
Phone +46 (0)8 58 60 10 00 / Fax +46 (0)8 58 60 10 01
www.ecdc.europa.eu
 
 
    Follow ECDC on:
 
 
Confidentiality Notice
If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively,
refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous
transmittal.
CONFIDENCIALIDAD. El contenido de este mensaje y el de cualquier documentación anexa es confidencial y va dirigido
únicamente al destinatario del mismo. Si Usted no es el destinatario, le solicitamos que nos lo indique, no comunique su
contenido a terceros y proceda a su destrucción.
CONFIDENTIALITY. The content of this message and any attached information is confidential and exclusively for the use of
the addresser. If you are not the addresser, we ask you to notify to the sender, do not pass its content and delete the original.